US2017080032A1PendingUtilityA1

Renovation and Repopulation of Decellularized Tissues and Cadaveric Organs by Stem Cells

61
Assignee: ANTHROGENESIS CORPPriority: Feb 14, 2001Filed: Apr 28, 2016Published: Mar 23, 2017
Est. expiryFeb 14, 2021(expired)· nominal 20-yr term from priority
A61P 7/00A61P 43/00A61P 7/06C12N 5/0605C12N 5/0068C12N 2513/00C12N 2509/00A61M 1/02C12N 2533/90C12N 5/0606A61M 2210/1466A61K 35/12A61L 27/3695A61L 2430/34A61M 2202/0462C12N 5/0678A61L 27/3834C12N 5/0663A61K 35/50A61M 2210/1458C12N 5/0607C12N 5/06
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Claims

exact text as granted — not AI-modified
1 .- 23 . (canceled) 
     
     
         24 . A method of treating an individual in need of repair of a mucosal membrane or intestinal lining, comprising administering to the individual isolated placental stem cells, wherein said isolated placental stem cells have been seeded onto a decellularized or synthetic tissue matrix, wherein said placental stem cells are obtained from a mammalian placenta that has been drained of cord blood, and wherein said placental stem cells
 (a) express antigens recognized by SH2, SH3 and SH4 antibodies;   (b) do not express MHC Class 2 antigens;   (c) are CD34 − , SSEA3 − , SSEA4 − , and OCT-4 + ;   (d) are SSEA3 − , SSEA4 − , OCT-4 +  and ABC-p + ; or   (e) are CD10 + , CD29 + , CD34 − , CD44 + , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 − , SSEA4 − , OCT-4 + , and ABC-p + .   
     
     
         25 . The method of  claim 24 , wherein said placental stem cells express antigens recognized by SH2, SH3 and SH4 antibodies. 
     
     
         26 . The method of  claim 24 , wherein said placental stem cells do not express MHC Class 2 antigens. 
     
     
         27 . The method of  claim 24 , wherein said placental stem cells are CD34 + , SSEA3 − , SSEA4 − , and OCT-4 + . 
     
     
         28 . The method of  claim 24 , wherein said placental stem cells are SSEA3 − , SSEA4 − , OCT-4 +  and ABC-p + . 
     
     
         29 . The method of  claim 24 , wherein said placental stem cells are CD10 + , CD29 + , CD34 − , CD44 + , CD45 − , CD54 + , CD90 + , SH2 + , SH3 + , SH4 + , SSEA3 − , SSEA4 − , OCT-4 + , and ABC-p + .

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.